ArticleToxicology reports2020
3D-bioprinted HepaRG cultures as a model for testing long term aflatoxin B1 toxicity
Article in Toxicology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Mechanobiology in Stem Cell-Based Bioprinting.Cell proliferation · 2026Review
- Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects.Current issues in molecular biology · 2024Review
- Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques.Cell & bioscience · 2024Review
- Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines.Discover nano · 2024Review
- Review
- Combining RNA Interference and RIG-I Activation to Inhibit Hepatitis E Virus Replication.Viruses · 2024Article
- 3D bioprinting of liver models: A systematic scoping review of methods, bioinks, and reporting quality.Materials today. Bio · 2024Article
- Review
- Xeno-Free 3D Bioprinted Liver Model for Hepatotoxicity Assessment.International journal of molecular sciences · 2024Article
- Application of 3D Bioprinting in Liver Diseases.Micromachines · 2023Review
- Three-Dimensional Bioprinting of Organoid-Based Scaffolds (OBST) for Long-Term Nanoparticle Toxicology Investigation.International journal of molecular sciences · 2023Article
- Evaluating the Suitability of 3D Bioprinted Samples for Experimental Radiotherapy: A Pilot Study.International journal of molecular sciences · 2022Article
- 3D bioprinting of complex tissues in vitro: state-of-the-art and future perspectives.Archives of toxicology · 2022Review
- Constructing biomimetic liver models through biomaterials and vasculature engineering.Regenerative biomaterials · 2022Review
- Bioprinting of a Hepatic Tissue Model Using Human-Induced Pluripotent Stem Cell-derived Hepatocytes for Drug-Induced Hepatotoxicity Evaluation.International journal of bioprinting · 2022Article
- Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform.International journal of molecular sciences · 2021Article
- Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.Acta pharmaceutica Sinica. B · 2021Review
- Current Strategies in Assessment of Nanotoxicity: Alternatives to In Vivo Animal Testing.International journal of molecular sciences · 2021Review
- Composite Bioinks With Mesoporous Bioactive Glasses-A Critical Evaluation of Results Obtained byFrontiers in bioengineering and biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years 3D-bioprinting technology has been developed as an alternative to animal testing. It possesses a great potential for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.